<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672772</url>
  </required_header>
  <id_info>
    <org_study_id>TTCC-2019-02</org_study_id>
    <secondary_id>TTC-CET-2020-01</secondary_id>
    <nct_id>NCT04672772</nct_id>
  </id_info>
  <brief_title>Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.</brief_title>
  <official_title>Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective observational study that aims to collect real world data on the cetuximab plus&#xD;
      paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell&#xD;
      carcinoma of the head and neck (SCCHN).&#xD;
&#xD;
      Assignment of a patient to a specific therapeutic strategy has been already decided in the&#xD;
      past according to normal routine clinical practice; the decision to prescribe a specific&#xD;
      treatment (between January 2012 and December 2018) was clearly dissociated from the decision&#xD;
      to include a patient in the present study.&#xD;
&#xD;
      The investigators will retrospectively collect the information for 500 patients diagnosed&#xD;
      with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as&#xD;
      first line for unresectable recurrent and/or metastatic disease, starting treatment with the&#xD;
      defined cetuximab plus paclitaxel regimen, in 20 hospital members of the &quot;Grupo Español de&#xD;
      Tratamiento de Tumores de Cabeza y Cuello (TTCC)&quot;, who express consent to participate in the&#xD;
      study or have not explicitly withheld consent for use of their data. The information from the&#xD;
      patients' medical records will be collected through the online database of the TTCC Group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective observational study that aims to collect real world data on the cetuximab plus&#xD;
      paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell&#xD;
      carcinoma of the head and neck (SCCHN) with the restriction that the data collection will&#xD;
      only be clinical data from patients who received paclitaxel 80 mg/m2 as a starting dose with&#xD;
      weekly cetuximab that could have been switched to biweekly during the maintenance phase.&#xD;
&#xD;
      The main objective will be to estimate the Progression-free survival (PFS) in patients&#xD;
      treated with paclitaxel 80 mg/m2 as a starting dose, with weekly cetuximab that could have&#xD;
      been switched to biweekly during the maintenance phase, as first line for recurrent and/or&#xD;
      metastatic SCCHN.&#xD;
&#xD;
      Secondary objectives include:&#xD;
&#xD;
      To determine the Overall Response Rate (ORR), Best Overall Response (BOR), Disease Control&#xD;
      Rate (DCR), overall survival (OS), duration of response (DoR), and safety in patients treated&#xD;
      with the defined cetuximab plus paclitaxel regimen.&#xD;
&#xD;
      To evaluate the percentage of long disease-free survivors (defined as patients disease-free&#xD;
      and alive at 2 years), and evaluate the percentage of long non-disease-free survivors&#xD;
      (defined as patients not disease free, but alive at 2 years.&#xD;
&#xD;
      Analyses of patient outcomes by prognostic subgroups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>The PFS time is defined as the time from start of study treatment (first administration of cetuximab or paclitaxel) to the date of progression or death, whichever occurs first. In patients without a PFS event, the PFS time will be censored on the date of the last radiological evaluation or on the date of the last study treatment received if the tumor response has not been evaluated after start of study treatment. If no PFS was observed prior to start of second line treatment, then the PFS time will be censored at the first date of second line treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Best overall response during study treatment with the categories complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) or not available (NA), as assessed by the responsible physician. The method used to assess BOR (e.g. RECIST and version) will be also recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Overall response rate, defined as the proportion of patients with CR or PR as BOR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>The proportion of patients with CR, PR or SD as BOR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events (AEs)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Safety will be studied as function of AEs frequency: The number of adverse events classified by type and intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Defined as time from start of study treatment until date of death due to any cause. In patients without death the OS time is censored at the last date known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity (RDI)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Relative dose intensity (RDI) defined as amount of drug administered per unit of time expressed as the fraction of that defined in the standard regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-related and compliance data</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Frequency and magnitude of dose interruptions, dose modifications and discontinuation of treatment classified by the cause of discontinuation including adverse events, relapse, medical decision, patient decision, death and loss of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>Defined as the time from the first occurrence of PR or CR as BOR until PD or death, whichever occurs first in patients with CR or PR as BOR.&#xD;
The censoring rules specified for PFS will be also applied for duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of long disease-free survivors</measure>
    <time_frame>Through study completion, average 1 year</time_frame>
    <description>The proportion of patients alive and disease-free at 2 years after start of study treatment. Only disease-free patients under first line treatment should be counted.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Recurrent and/or metastatic SCCHN</arm_group_label>
    <description>Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Weekly cetuximab at starting dose, that could be switched to biweekly</description>
    <arm_group_label>Recurrent and/or metastatic SCCHN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel at starting dose of 80 mg/m2</description>
    <arm_group_label>Recurrent and/or metastatic SCCHN</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus&#xD;
        paclitaxel regimen as first line for unresectable R/M disease, starting treatment with the&#xD;
        defined cetuximab plus paclitaxel regimen, between January 2012 and December 2018 in 20&#xD;
        hospital members of the &quot;Grupo Español de Tratamiento de Tumores de Cabeza y Cuello&quot;, who&#xD;
        express consent to participate in the study or have not explicitly withheld consent for use&#xD;
        of their data.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed recurrent and/or metastatic head and neck&#xD;
             squamous-cell carcinoma including oral cavity, oropharynx, hypopharynx and larynx.&#xD;
&#xD;
        Note: Histological confirmation is required at the diagnosis of the primary. Not for&#xD;
        recurrence and/or metastatic stages when radiological or clinical confirmation is valid&#xD;
&#xD;
          -  Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose&#xD;
             with weekly cetuximab, that could have been switched to biweekly during the&#xD;
             maintenance phase, as a first line regimen in recurrent and/or metastatic disease.&#xD;
&#xD;
          -  Start of first cycle of paclitaxel plus cetuximab between 1 January 2012, and 31&#xD;
             December 2018.&#xD;
&#xD;
          -  Aged ≥ 18 years at the time of diagnosis of R/M SCCHN.&#xD;
&#xD;
          -  Voluntary written consent, if applicable*&#xD;
&#xD;
               -  Note: Waiver of consent could be acceptable after all reasonable efforts and&#xD;
                  procedures have been followed and exhausted, and when an explicit refusal to sign&#xD;
                  the informed consent or refusal for use of data, or a revocation of consent by&#xD;
                  the patient has not been obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed R/M SCCHN, who have also an unknown primary&#xD;
             tumor or nasopharyngeal cancer or a non-squamous head &amp; neck cancer.&#xD;
&#xD;
          -  Patients who received the paclitaxel and cetuximab regimen for the first time in&#xD;
             recurrent and/or metastatic disease as a second or subsequent line.&#xD;
&#xD;
          -  Eastern Cooperative. Oncology Group (ECOG) performance status &gt; 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz Cirauqui Cirauqui, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catalá d'Oncologia (ICO) Badalona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Rubió Casadevall, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catalá d'Oncologia (ICO) Girona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Nepote</last_name>
    <phone>0034934344412</phone>
    <phone_ext>102</phone_ext>
    <email>investigacion@mfar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Luisa Duran Sanchez, Study coordinator (TTCC)</last_name>
    <phone>0034690756714</phone>
    <email>mduran@ttccgrupo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <state>Castilla La Mancha</state>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catalá d'Oncologia (ICO) Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Cataluña</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catalá d'Oncologia (ICO) Girona</name>
      <address>
        <city>Girona</city>
        <state>Cataluña</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynalds (ICO-Hospitalet)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Navarra (PAMPLONA)</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias (TENERIFE)</name>
      <address>
        <city>San Cristobal de la Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034934344412</phone>
      <phone_ext>102</phone_ext>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>recurrent and/or metastatic</keyword>
  <keyword>retrospective observational study</keyword>
  <keyword>Squamous Cell Carcinoma of Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

